

# Changes, Patterns and Predictors of Sexually Transmitted Infections in Gay and Bisexual Men Using PrEP

## Interim Analysis from the PrEPX Study

**M Traeger**, J. Asselin, B. Price, V. Cornelisse, N. Roth, J. Willcox, B.K. Tee, C. Fairley, C. Chang, J. Armishaw, O. Vujovic, M. Penn, P. Cundill, G. Forgan-Smith, J. Gall, C. Pickett, L. Lal, A. Mak, T. Spelman, L. Nguyen, D. Murphy, K. Ryan, C. El-Hayek, S. Ruth, C. Batrouney, J. Lockwood, J. Hoy, R. Grant, M. Hellard, M. Stoové\*, E. Wright\*, *on behalf of the PrEPX Study Team*

\*Co-senior authors

**Michael Traeger, MSc(Epi)**

The Burnet Institute, Melbourne, Australia

International AIDS Conference, Amsterdam, July 2018  
Abstract THAC0502

South Australian Sponsor and Research Partner:



Government  
of South Australia



MONASH University



Health  
and Human  
Services



**Burnet Institute**  
Medical Research. Practical Action.



**thorneharbour**  
health\*



TheAlfred



**Burnet Institute**  
Medical Research. Practical Action.




# Conflicts of interest

Nothing to disclose

# Background

## PrEP in Australia

Small pilot studies begin  
in Melbourne and Sydney




1. Lee et al. 2016
2. Lee et al. 2017

# Background

## PrEP in Australia

Small pilot studies begin  
in Melbourne and Sydney



1. Lee et al. 2016

2. Lee et al. 2017

# Background

## PrEP in Australia

Small pilot studies begin in Melbourne and Sydney

Large implementation studies across Victoria and NSW begin enrolment

Daily PrEP approved by TGA

6% of GBM in Melbourne using PrEP<sup>1</sup>



1. Lee et al. 2016  
2. Lee et al. 2017

# Background

## PrEP in Australia

Small pilot studies begin in Melbourne and Sydney

Daily PrEP approved by TGA

Large implementation studies across Victoria and NSW begin enrolment

PrEP listed for public subsidy



2014

2015

2016

2017

2018

6% of GBM in Melbourne using PrEP<sup>1</sup>

18% of GBM in Melbourne using PrEP<sup>2</sup>

1. Lee et al. 2016  
2. Lee et al. 2017

# Background


## PrEP in Australia

Small pilot studies begin in Melbourne and Sydney

Daily PrEP approved by TGA

Large implementation studies across Victoria and NSW begin enrolment

PrEP listed for public subsidy



- More than 15,000 enrolled in PrEP studies nationwide
- PrEP currently available for \$39.90 / month
- PrEP can be prescribed by any doctor or nurse practitioner

1. Lee et al. 2016  
2. Lee et al. 2017

# The PrEPX Study

## Victoria, Australia

- **Multi-site implementation study**


More than 10 metropolitan,  
regional and rural clinics

- **Study duration July 2016 – March 2018**

4,275 participants, mostly gay and bisexual men  
1000 enrolled in first 3 weeks

- **Participants returned every 3 months**

HIV and STI testing  
Behavioural survey





# The PrEPX Study

## Victoria, Australia

- **Multi-site implementation study**

More than 10 metropolitan,  
regional and rural clinics

- **Study duration July 2016 – March 2018**


4,275 participants, mostly gay and bisexual men  
1000 enrolled in first 3 weeks

- **Participants returned every 3 months**

HIV and STI testing  
Behavioural survey

- **Primary outcome: Reduction in population-level HIV incidence**

- **Secondary outcome: Sexually transmissible infections among PrEP users**



# STIs in PrEP Users

- Evidence suggests STIs increase among PrEP users<sup>1,2</sup>

1. Traeger et al. 2018
2. Lal et al. 2017
3. Kirby Institute 2017
4. Holt et al. 2017

# STIs in PrEP Users

- Evidence suggests STIs increase among PrEP users<sup>1,2</sup>
- Many studies lack pre-PrEP STI incidence data

1. Traeger et al. 2018
2. Lal et al. 2017
3. Kirby Institute 2017
4. Holt et al. 2017

# STIs in PrEP Users

- Evidence suggests STIs increase among PrEP users<sup>1,2</sup>
- Many studies lack pre-PrEP STI incidence data
- High screening in PrEP users introduces detection bias  
Australian PrEP guidelines recommend quarterly STI screening

1. Traeger et al. 2018
2. Lal et al. 2017
3. Kirby Institute 2017
4. Holt et al. 2017

# STIs in PrEP Users

- **Evidence suggests STIs increase among PrEP users<sup>1,2</sup>**
- **Many studies lack pre-PrEP STI incidence data**
- **High screening in PrEP users introduces detection bias**  
Australian PrEP guidelines recommend quarterly STI screening
- **STI rates were increasing prior to the introduction of PrEP**  
Gonorrhoea, chlamydia and syphilis increasing among Australian GBM since 2010<sup>3</sup>
- **Consistent condom use has been decreasing**  
Condomless sex among Australian GBM increased from 27% to 39%, 2000 to 2015<sup>4</sup>

1. Traeger et al. 2018
2. Lal et al. 2017
3. Kirby Institute 2017
4. Holt et al. 2017

# Aims

- 1. Calculate STI incidence and distribution among PrEPX participants**
- 2. Explore behavioural characteristics associated with STI risk**
- 3. Identify changes in STI incidence before and after using PrEP**

# Data Collection

## Australian Collaboration for Coordinated Enhanced Sentinel Surveillance

A national STI and BBV sentinel surveillance system

Over 100 sites nationally



- **Most participants enrolled in PrEPX at ACCESS clinics**
  - Track participant movement between clinics
  - Include between-study-visit test events

# Participant characteristics

Participants enrolled at ACCESS sites	n=2,981
Age (median, range)	34 (16-72)
Gay or bisexual	2,922 (98%)
Transgender Female	4 (0.1%)
Transgender Male	11 (0.4%)
Used PrEP before enrolment	834 (28%)
STI diagnosed in 3 months prior to / at baseline	775 (26%)
CRAI in 3 months prior to baseline	1430 (48%)



# 1. STIs during PrEPX follow-up


## STI Incidence

- Study period July 2016 – March 2018
- Total follow-up: 3180 person-years (median, 14.4 months)

	Incidence rate (per 100 person-years)
Any STI	91.9
Chlamydia	44.8
Gonorrhoea	38.6
Syphilis	8.0
Any rectal infection	56.6
Any urethral infection	22.4
Any pharyngeal infection	23.5


# 1. STIs during PrEPX follow-up

## Distribution of STIs




# 1. STIs during PrEPX follow-up

## Distribution of STIs



# 1. STIs during PrEPX follow-up

## Distribution of STIs



## 2. Behavioural predictors of STIs

### Methods

- Behavioural survey completed at baseline and every three months
- Cox proportional hazards regression model
  - Time-varying behaviours were updated at each visit
  - Outcome was diagnosis of chlamydia, gonorrhoea or syphilis
  - Allowed for multiple diagnoses

## 2. Behavioural predictors of STIs

### Cox proportional hazards model

	Adjusted Hazard Ratio (95% CI)	p
Age (5 year increase)	0.94 (0.90 – 0.97)	0.001
Diagnosed with an STI 3 months prior to enrolment	1.24 (1.05 – 1.45)	0.010
CRAI w/ casual partner 3 months prior to enrolment	1.15 (1.01 – 1.32)	0.039
GHB use during sex in last 6 months	1.24 (1.02 – 1.51)	0.027

## 2. Behavioural predictors of STIs

### Cox proportional hazards model

	Adjusted hazard ratio (95% CI)	p
<b>Number of anal sex partners in last 6 months</b>		
2-5	-reference-	
6-10	1.27 (1.04 – 1.57)	0.020
11-20	1.88 (1.46 – 2.41)	<0.001
21 - 50	2.13 (1.54 – 2.95)	<0.001
more than 50	2.55 (1.59 – 4.09)	<0.001
<b>Group sex in last 6 months</b>		
None	-reference-	
Once / a few times	1.28 (1.10 – 1.50)	0.002
At least monthly	1.47 (1.16 – 1.85)	0.001
At least weekly	1.67 (1.16 – 2.41)	0.006
<b>Condom use with casual partners in last 6 months</b>		
Always	-reference-	
Usually (>50%)	1.38 (0.96 - 1.97)	0.081
Sometimes (<50%)	1.38 (0.96 - 1.99)	0.080
Never	1.31 (0.88 - 1.97)	0.183

## 2. Behavioural predictors of STIs

### Cox proportional hazards model

	Adjusted hazard ratio (95% CI)	p
<b>Number of anal sex partners in last 6 months</b>		
2-5	-reference-	
6-10	1.27 (1.04 – 1.57)	0.020
11-20	1.88 (1.46 – 2.41)	<0.001
21 - 50	2.13 (1.54 – 2.95)	<0.001
more than 50	2.55 (1.59 – 4.09)	<0.001
<b>Group sex in last 6 months</b>		
None	-reference-	
Once / a few times	1.28 (1.10 – 1.50)	0.002
At least monthly	1.47 (1.16 – 1.85)	0.001
At least weekly	1.67 (1.16 – 2.41)	0.006
<b>Condom use with casual partners in last 6 months</b>		
Always	-reference-	
Usually (>50%)	1.38 (0.96 - 1.97)	0.081
Sometimes (<50%)	1.38 (0.96 - 1.99)	0.080
Never	1.31 (0.88 - 1.97)	0.183



## 2. Behavioural predictors of STIs

### Cox proportional hazards model

	Adjusted hazard ratio (95% CI)	p
<b>Number of anal sex partners in last 6 months</b>		
2-5	-reference-	
6-10	1.27 (1.04 – 1.57)	0.020
11-20	1.88 (1.46 – 2.41)	<0.001
21 - 50	2.13 (1.54 – 2.95)	<0.001
more than 50	2.55 (1.59 – 4.09)	<0.001
<b>Group sex in last 6 months</b>		
None	-reference-	
Once / a few times	1.28 (1.10 – 1.50)	0.002
At least monthly	1.47 (1.16 – 1.85)	0.001
At least weekly	1.67 (1.16 – 2.41)	0.006
<b>Condom use with casual partners in last 6 months</b>		
Always	-reference-	
Usually (>50%)	1.38 (0.96 - 1.97)	0.081
Sometimes (<50%)	1.38 (0.96 - 1.99)	0.080
Never	1.31 (0.88 - 1.97)	0.183

## 2. Behavioural predictors of STIs

### Cox proportional hazards model

	Adjusted hazard ratio (95% CI)	p
<b>Number of anal sex partners in last 6 months</b>		
2-5	-reference-	
6-10	1.27 (1.04 – 1.57)	0.020
11-20	1.88 (1.46 – 2.41)	<0.001
21 - 50	2.13 (1.54 – 2.95)	<0.001
more than 50	2.55 (1.59 – 4.09)	<0.001
<b>Group sex in last 6 months</b>		
None	-reference-	
Once / a few times	1.28 (1.10 – 1.50)	0.002
At least monthly	1.47 (1.16 – 1.85)	0.001
At least weekly	1.67 (1.16 – 2.41)	0.006
<b>Condom use with casual partners in last 6 months</b>		
Always	-reference-	
Usually (>50%)	1.38 (0.96 - 1.97)	0.081
Sometimes (<50%)	1.38 (0.96 - 1.99)	0.080
Never	1.31 (0.88 - 1.97)	0.183

### 3. Change in STIs before and after PrEPX

#### Methods

- **Subgroup analysis (n=1,378)**  
Participants who had been visiting ACCESS clinics before enrolment
- **Calculated STI incidence before and after enrolment**  
Comparison: 12 months before enrolment vs During PrEPX follow-up
- **Negative binomial regression model**  
Adjusted for change in testing frequency  
Included individual testing rate before and after as a confounding variable



### 3. Change in STIs before and after PrEPX

#### Incidence rates before and after PrEPX

Incidence rate (per 100 person-years)				
	1 year before PrEPX	During PrEPX	IRR (95% CI)	P-value
Any STI	69.5	98.4	1.42 (1.29 – 1.56)	<0.001
Chlamydia	33.3	49.0	1.47 (1.30 – 1.66)	<0.001
Gonorrhoea	30.1	42.3	1.38 (1.21 – 1.57)	0.003
Syphilis	6.8	8.7	1.28 (0.98 – 1.68)	0.065

### 3. Change in STIs before and after PrEPX

#### Incidence rates before and after PrEPX

Incidence rate (per 100 person-years)				
	1 year before PrEPX	During PrEPX	IRR (95% CI)	P-value
Any STI	69.5	98.4	1.42 (1.29 – 1.56)	<0.001
Chlamydia	33.3	49.0	1.47 (1.30 – 1.66)	<0.001
Gonorrhoea	30.1	42.3	1.38 (1.21 – 1.57)	0.003
Syphilis	6.8	8.7	1.28 (0.98 – 1.68)	0.065
Rectal Infections	45.0	62.3	1.39 (1.22 – 1.57)	<0.001
Pharyngeal Infections	16.3	23.3	1.43 (1.20 – 1.70)	<0.001
Urethral Infections	17.6	25.9	1.47 (1.21 – 1.77)	<0.001

### 3. Change in STIs before and after PrEPX

#### Incidence rates before and after PrEPX

Incidence rate (per 100 person-years)				
	1 year before PrEPX	During PrEPX	IRR (95% CI)	P-value
Any STI	69.5	98.4	1.42 (1.29 – 1.56)	<0.001
Chlamydia	33.3	49.0	1.47 (1.30 – 1.66)	<0.001
Gonorrhoea	30.1	42.3	1.38 (1.21 – 1.57)	0.003
Syphilis	6.8	8.7	1.28 (0.98 – 1.68)	0.065
Rectal Infections	45.0	62.3	1.39 (1.22 – 1.57)	<0.001
Pharyngeal Infections	16.3	23.3	1.43 (1.20 – 1.70)	<0.001
Urethral Infections	17.6	25.9	1.47 (1.21 – 1.77)	<0.001
Previous PrEP users	92.4	104.1	1.13 (0.98 – 1.28)	0.072
PrEP naïve participants	55.1	94.2	1.71 (1.49 – 1.98)	<0.001

### 3. Change in STIs before and after PrEPX

Overall testing rate increased by 48% in PrEP-naïve participants



### 3. Change in STIs before and after PrEPX

Overall testing rate increased by 48% in PrEP-naïve participants

#### Adjusted negative binomial model

	Unadjusted		Adjusted*	
	IRR (95% CI)	p-value	aIRR (95% CI)	p-value
<b>PrEP naïve participants</b>				
Any STI	1.71 (1.49 – 1.98)	<0.001	<b>1.21 (1.06 – 1.39)</b>	<b>0.006</b>

\*Adjusted for differential testing frequency

### 3. Change in STIs before and after PrEPX

Overall testing rate increased by 48% in PrEP-naïve participants

#### Adjusted negative binomial model

	Unadjusted		Adjusted*	
	IRR (95% CI)	p-value	aIRR (95% CI)	p-value
<b>PrEP naïve participants</b>				
Any STI	1.71 (1.49 – 1.98)	<0.001	<b>1.21 (1.06 – 1.39)</b>	<b>0.006</b>
Chlamydia	1.84 (1.55 – 2.20)	<0.001	<b>1.38 (1.13 – 1.66)</b>	<b>0.001</b>
Gonorrhoea	1.69 (1.42 – 2.01)	0.003	1.11 (0.92 – 1.34)	0.263
Syphilis	1.24 (0.87 – 1.78)	0.065	0.93 (0.62 – 1.40)	0.744

\*Adjusted for differential testing frequency

# Summary

## 1. STIs during PrEPX follow-up

- Overall STI incidence of 91/100 person-years
- Over half of participants (52%) were not diagnosed with an STI
- STIs were highly concentrated among PrEP users experiencing repeat infections

# Summary

## 1. STIs during PrEPX follow-up

- Overall STI incidence of 91/100 person-years
- Over half of participants (52%) were not diagnosed with an STI
- STIs were highly concentrated among PrEP users experiencing repeat infections

## 2. Behavioural predictors of STI risk

- STI risk among PrEPX participants was driven more by numbers of partners and participation in group sex rather than condom use

# Summary

## 1. STIs during PrEPX follow-up

- Overall STI incidence of 91/100 person-years
- Over half of participants (52%) were not diagnosed with an STI
- STIs were highly concentrated among PrEP users experiencing repeat infections

## 2. Behavioural predictors of STI risk

- STI risk among PrEPX participants was driven more by numbers of partners and participation in group sex rather than condom use

## 3. Before and after PrEP

- STI incidence increased among GBM after enrolling in PrEPX, especially among those starting PrEP for the first time
- Partly explained by increase in testing frequency
- After adjusting for testing frequency, GBM using PrEP for the first time experienced a moderate but significant increase for any STI diagnosis and chlamydia infection

# Implications

- **STIs increased at the individual-level after initiating PrEP**
  - However, high screening rates reduce duration of infection
  - Models indicate that increased screening among PrEP users may lead to an overall decrease in population-level STI incidence<sup>1</sup>
  - Monitor behavioural change at both individual and population-level

1. Jenness et al. 2017

# Implications

- **STIs increased at the individual-level after initiating PrEP**
  - However, high screening rates reduce duration of infection
  - Models indicate that increased screening among PrEP users may lead to an overall decrease in population-level STI incidence<sup>1</sup>
  - Monitor behavioural change at both individual and population-level
- **PrEP as a program - PrEP use must be combined with regular STI testing**

Supports current Australian guidelines for 3 monthly STI testing

1. Jenness et al. 2017

# Implications

- **STIs increased at the individual-level after initiating PrEP**
  - However, high screening rates reduce duration of infection
  - Models indicate that increased screening among PrEP users may lead to an overall decrease in population-level STI incidence<sup>1</sup>
  - Monitor behavioural change at both individual and population-level
- **PrEP as a program - PrEP use must be combined with regular STI testing**

Supports current Australian guidelines for 3 monthly STI testing
- **Strategies can be targeted towards PrEP users experiencing high rates of reinfection**

1. Jenness et al. 2017



# Implications

- **STIs increased at the individual-level after initiating PrEP**
  - However, high screening rates reduce duration of infection
  - Models indicate that increased screening among PrEP users may lead to an overall decrease in population-level STI incidence<sup>1</sup>
  - Monitor behavioural change at both individual and population-level
- **PrEP as a program - PrEP use must be combined with regular STI testing**

Supports current Australian guidelines for 3 monthly STI testing
- **Strategies can be targeted towards PrEP users experiencing high rates of reinfection**
- **Community involvement critical to success of future measures to reduce STIs**

1. Jenness et al. 2017

# Acknowledgements

## PrEPX Study Team

### Edwina Wright – Principal Investigator

Brian Price  
Anne Mak  
Luxi Lal  
Dean Murphy  
Jude Armishaw  
Timmy Lockwood  
Olga Vujovic  
Christina Chang  
Vincent Cornelisse

## Burnet Institute

### Mark Stoové

Jason Asselin  
Long Nguyen  
Carol El-Hayek  
Kat Ryan

## Centre for Social Research and Health

Dean Murphy  
John De Wit

## Study Clinics

**Prahran Market Clinic:** Norm Roth  
**Northside Clinic:** Jeff Wilcox  
**MSHC:** Kit Fairley  
**PRONTO!:** Matt Penn  
**Centre Clinic:** BK Tee  
**ERA Health:** George Forgan-Smith  
**Alfred HIP Clinic and Nurse Led Clinics**

## Pharmacies

**John Silverii's Pharmacy:** John Silverii  
**Newton and Leung Pharmacy:** Johnny Phu  
**Melbourne Sexual Health:** Anne Mak  
**Alfred Clinical Trials Pharmacy:** Anne Mak  
**Healthsmart:** Joseph Tesoriero  
**Central Pharmacy:** Manoj Vassan, Kie Lim  
**Russell Frajman Pharmacy:** Russell Frajman

## ACCESS

Burnet Institute, Kirby Institute & NRL

## Community Organisations

**VAC:** Simon Ruth, Colin Batrouney, Jeremy Wiggins  
**PrEP'DForChange:** Chris Williams  
**PrEPaccessNOW:** Jeff Montgomery & Michael Whelan  
**Living Positive Victoria:** Brent Allen  
**Victorian Aboriginal Controlled Community Health Organisation:** Kat Byron  
**Centre for Culture Ethnicity and Health:** Alison Coelho  
**Harm Reduction Victoria:** Jenny Kelsall

## Funding Bodies

**Victorian Department of Health and Human Services:** Michael West  
**Alfred Health (Study sponsor):** Andrew Way  
**Victorian AIDS Council\*:** Simon Ruth

## Research Participants

PrEPX participants  
Participants in previous PrEP research  
Animals in PrEP efficacy studies

# References

- Lee et al. (2016). Gay Community Periodic Survey: Melbourne 2016. Sydney, Centre for Social Research in Health, UNSW Australia.
- Lee et al. (2018). Gay Community Periodic Survey: Melbourne 2018. Sydney, Centre for Social Research in Health, UNSW Australia.
- Traeger M, et al. (2018). Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. Clin Infect Dis, ciy182.
- Lal L, et al. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS. 2017 Jul;31(12):1709–14.
- Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2017. Sydney: Kirby Institute, UNSW Sydney; 2017.
- Holt M et al. (2017). Adapting behavioural surveillance to antiretroviral-based HIV prevention: reviewing and anticipating trends in the Australian Gay Community Periodic Surveys. Sexual Health 14:72-79.
- Jenness, S. M., et al. (2017). "Incidence of Gonorrhoea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study." Clin Infect Dis 65(5): 712-718.

## **Michael Traeger, MScEpi**

Burnet Institute

[michael.traeger@burnet.edu.au](mailto:michael.traeger@burnet.edu.au)



**Burnet Institute**  
Medical Research. Practical Action.



Equity Through Better Health

**[burnet.edu.au](http://burnet.edu.au)**

85 Commercial Road Melbourne, Victoria, 3004